BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol 2021;72:136-45. [PMID: 32544511 DOI: 10.1016/j.semcancer.2020.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Xia Y, Zhou X, Yu H, Tan Y, Du Y, Zhang Q, Wu Y. Current landscape of personalized clinical treatments for triple-negative breast cancer. Front Pharmacol 2022;13:977660. [DOI: 10.3389/fphar.2022.977660] [Reference Citation Analysis]
2 Abdelraouf EM, Hussein RRS, Shaaban AH, El-Sherief HAM, Embaby AS, Abd El-Aleem SA. Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. Life Sci 2022;308:120967. [PMID: 36116530 DOI: 10.1016/j.lfs.2022.120967] [Reference Citation Analysis]
3 Vtorushin S, Dulesova A, Krakhmal N. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. J Zhejiang Univ Sci B 2022;23:617-24. [PMID: 35953756 DOI: 10.1631/jzus.B2200113] [Reference Citation Analysis]
4 Meng L, Song K, Li S, Kang Y. Exosomes: Small Vesicles with Important Roles in the Development, Metastasis and Treatment of Breast Cancer. Membranes 2022;12:775. [DOI: 10.3390/membranes12080775] [Reference Citation Analysis]
5 Nelczyk AT, Ma L, Gupta AD, Gamage HEV, McHenry MT, Henn MA, Kadiri M, Wang Y, Krawczynska N, Bendre S, He S, Shahoei SH, Madak-Erdogan Z, Hsiao SH, Saleh T, Carpenter V, Gewirtz DA, Spinella MJ, Nelson ER. The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer. Biochim Biophys Acta Mol Basis Dis 2022;:166515. [PMID: 35932893 DOI: 10.1016/j.bbadis.2022.166515] [Reference Citation Analysis]
6 Huo W, Yang X, Wang B, Cao L, Fang Z, Li Z, Liu H, Liang X, Zhang J, Jin Y. Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121722] [Reference Citation Analysis]
7 Messeha SS, Zarmouh NO, Antonie L, Soliman KFA. Sanguinarine Inhibition of TNF-α-Induced CCL2, IKBKE/NF-κB/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells. IJMS 2022;23:8329. [DOI: 10.3390/ijms23158329] [Reference Citation Analysis]
8 Abreu de Oliveira WA, El Laithy Y, Bruna A, Annibali D, Lluis F. Wnt Signaling in the Breast: From Development to Disease. Front Cell Dev Biol 2022;10:884467. [DOI: 10.3389/fcell.2022.884467] [Reference Citation Analysis]
9 Chen X, Shu C, Li W, Hou Q, Luo G, Yang K, Wu X. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. J Med Chem 2022. [PMID: 35447031 DOI: 10.1021/acs.jmedchem.2c00063] [Reference Citation Analysis]
10 Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy. J Med Chem 2022. [PMID: 35442700 DOI: 10.1021/acs.jmedchem.2c00135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yang R, Li Y, Wang H, Qin T, Yin X, Ma X. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed 2022;3:8. [PMID: 35243562 DOI: 10.1186/s43556-022-00071-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Yang X, Zhao M, Wu Z, Chen C, Zhang Y, Wang L, Guo Q, Wang Q, Liang S, Hu S, Duan Y, Sun Y. Nano-ultrasonic Contrast Agent for Chemoimmunotherapy of Breast Cancer by Immune Metabolism Reprogramming and Tumor Autophagy. ACS Nano 2022;16:3417-31. [PMID: 35156370 DOI: 10.1021/acsnano.2c00462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Pantelaiou-Prokaki G, Mieczkowska I, Schmidt GE, Fritzsche S, Prokakis E, Gallwas J, Wegwitz F. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer. Clin Epigenetics 2022;14:7. [PMID: 35016723 DOI: 10.1186/s13148-022-01228-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. Front Oncol 2021;11:769280. [PMID: 34900718 DOI: 10.3389/fonc.2021.769280] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
15 Wu Q, Tang X, Zhu W, Li Q, Zhang X, Li H. The Potential Prognostic Role of Oligosaccharide-Binding Fold-Containing Protein 2A (OBFC2A) in Triple-Negative Breast Cancer. Front Oncol 2021;11:751430. [PMID: 34868954 DOI: 10.3389/fonc.2021.751430] [Reference Citation Analysis]
16 Qiu X, Qu Y, Guo B, Zheng H, Meng F, Zhong Z. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer. J Control Release 2021;341:498-510. [PMID: 34883139 DOI: 10.1016/j.jconrel.2021.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
17 Zhu X, Li L. Circ-DONSON Knockdown Inhibits Cell Proliferation and Radioresistance of Breast Cancer Cells via Regulating SOX4. J Oncol 2021;2021:8461740. [PMID: 34853591 DOI: 10.1155/2021/8461740] [Reference Citation Analysis]
18 Huang J, Lai W, Wang Q, Tang Q, Hu C, Zhou M, Wang F, Xie D, Zhang Q, Liu W, Zhang Z, Zhang R. Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles. Int J Nanomedicine 2021;16:7497-515. [PMID: 34803378 DOI: 10.2147/IJN.S321071] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Shin E, Koo JS. Glucose Metabolism and Glucose Transporters in Breast Cancer. Front Cell Dev Biol 2021;9:728759. [PMID: 34552932 DOI: 10.3389/fcell.2021.728759] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
20 Zhao M, Yang X, Fu H, Chen C, Zhang Y, Wu Z, Duan Y, Sun Y. Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles. ACS Appl Mater Interfaces 2021;13:32763-79. [PMID: 34235912 DOI: 10.1021/acsami.1c07323] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
21 Qian Y, Zhang J, Xu R, Li Q, Shen Q, Zhu G. Nanoparticles based on polymers modified with pH-sensitive molecular switch and low molecular weight heparin carrying Celastrol and ferrocene for breast cancer treatment. Int J Biol Macromol 2021;183:2215-26. [PMID: 34097964 DOI: 10.1016/j.ijbiomac.2021.05.204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Huang Z, Pan J, Wang H, Du X, Xu Y, Wang Z, Chen D. Prognostic Significance and Tumor Immune Microenvironment Heterogenicity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer. Front Cell Dev Biol 2021;9:657547. [PMID: 33928086 DOI: 10.3389/fcell.2021.657547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
23 Cipriano É, Mesquita A. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) 2021;15:11782234211002491. [PMID: 33814914 DOI: 10.1177/11782234211002491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zheng Q, Gu X, Yang Q, Chu Q, Dai Y, Chen Z. DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression. Clin Chim Acta 2021;517:1-8. [PMID: 33607068 DOI: 10.1016/j.cca.2021.02.006] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
25 Yang J, Lee SJ, Kwon Y, Ma L, Kim J. Tumor suppressive function of Matrin 3 in the basal-like breast cancer. Biol Res 2020;53:42. [PMID: 32977861 DOI: 10.1186/s40659-020-00310-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 Han Y, Wang J, Xu B. Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. Breast 2020;54:114-20. [PMID: 32979771 DOI: 10.1016/j.breast.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]